France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Multiple myeloma pathogenesis is marked by incredibly complex processes that range beyond primary or acquired genetic alterations, with factors in the ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 ...

Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug ...

An update from BB Biotech ( ($CH:BION) ) is now available. In Q2 2025, BB Biotech outperformed the Nasdaq Biotech Index, with a 10.2% increase in ...

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...